---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-097680"
form_type: "8-K"
ticker: "CPHI"
cik: "0001106644"
company_name: "CHINA PHARMA HOLDINGS, INC."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T08:46:54.019159+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# China Pharma acquires COPD drug patent for $1.65M in restricted stock; royalty of 15% net profit

## Summary
- Subsidiary Helpson enters Technology Transfer Agreement with Tao Liu for a COPD drug combination patent.
- Consideration: 15,000,000 restricted shares at $0.11/share ($1.65M) under Regulation S exemption.
- Helpson to pay 15% of net profit from product sales annually for 10 years if product is profitable.
- Transferor to provide R&D, registration, and technical services in Haikou.
- Shares are unregistered and issued in an offshore transaction to a non-U.S. person.

## SEC filing metadata
- accession: 0001213900-23-097680
- form_type: 8-K
- ticker: CPHI
- cik: 0001106644
- company_name: CHINA PHARMA HOLDINGS, INC.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1106644/000121390023097680/0001213900-23-097680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1106644/000121390023097680/ea190499-8k_chinapharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-097680
- JSON: https://secwatch.observer/filing/0001213900-23-097680.json
- Plain text: https://secwatch.observer/filing/0001213900-23-097680.txt

## Key facts
- Material Agreements
  CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Tao Liu valued at $1.65 million (effective 2023-12-15).
  - Action: entry
  - Counterparty: Tao Liu
  - Value: $1.65 million
  - Effective: 2023-12-15
  source text: On December 15, 2023, Hainan Helpson Medical & Biotechnology Co., Ltd (“ Helpson ”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “ Company ”), entered into a Technology Transfer Agreement (the “ Agreement ”) with Tao Liu (the “ Transferor ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1106644/000121390023097680/0001213900-23-097680-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.